Atezolizumab and bevacizumab combination compared with sorafenib as the first‐line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost‐effectiveness analysis in China and the United states

2021 ◽  
Vol 41 (5) ◽  
pp. 1097-1104
Author(s):  
Feng Wen ◽  
Hanrui Zheng ◽  
Pengfei Zhang ◽  
Weiting Liao ◽  
Kexun Zhou ◽  
...  
Keyword(s):  
United States ◽  
Hepatocellular Carcinoma ◽  
Cost Effectiveness ◽  
Systemic Treatment ◽  
The United States ◽  
Cost Effectiveness Analysis ◽  
First Line ◽  
Effectiveness Analysis ◽  
Unresectable Hepatocellular Carcinoma

scholarly journals Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States

Hepatology ◽  
2017 ◽  
Vol 65 (4) ◽  
pp. 1237-1248 ◽  
Author(s):  
Benjamin Cadier ◽  
Julie Bulsei ◽  
Pierre Nahon ◽  
Olivier Seror ◽  
Alexis Laurent ◽  
...  
Keyword(s):  
United States ◽  
Hepatocellular Carcinoma ◽  
Cost Effectiveness ◽  
Early Detection ◽  
The United States ◽  
Cost Effectiveness Analysis ◽  
Curative Treatment ◽  
Effectiveness Analysis
Sign in / Sign up

Export Citation Format

Share Document